Tozorakimab治疗中重度特应性皮炎:2a期随机对照试验(FRONTIER-2)
FRONTIER-2是一项随机、双盲、安慰剂对照2a期研究,纳入148例中重度特应性皮炎成人患者,评估tozorakimab(抗IL-33单抗)皮下注射每4周一次共4次的安全性与疗效。主要终点第16周EASI评分较基线百分比变化在各剂量组与安慰剂组间均无统计学显著差异,但600mg组EASI-75和IGA 0/1应答率数值上高于安慰剂组,药物耐受性良好。
要点
- Tozorakimab各剂量组主要终点EASI变化与安慰剂无统计学显著差异。
- 600mg组EASI-75应答率18.2% vs 安慰剂7.1%,差异无统计学意义。
- 药代动力学呈剂量依赖性,免疫原性发生率低,药物耐受性良好。
核心结论
- FRONTIER-2研究未显示tozorakimab在主要终点上优于安慰剂,但观察到应答率数值升高。
研究设计与样本
- 随机、安慰剂对照、平行组、双盲2a期研究,2019年12月9日至2022年9月20日在6国32中心开展。
- 148例中重度特应性皮炎成人患者按3:1:1:3随机接受安慰剂、tozorakimab 60mg、300mg或600mg皮下注射每4周一次共4次。
主要发现
- 主要终点第16周EASI评分较基线百分比变化:60mg组差异1.3(90%CI -13.7, 16.2),p=0.888;300mg组差异5.9(90%CI -10.4, 22.1),p=0.549;600mg组差异-1.7(90%CI -13.4, 10.0),p=0.807。
- 第16周EASI-75应答率600mg组18.2% vs 安慰剂7.1%(p=0.094),IGA 0/1应答率9.1% vs 1.8%(p=0.113)。
- 血清药代动力学呈剂量依赖性,免疫原性发生率低,tozorakimab耐受性良好。
临床怎么用
- 当前证据不支持tozorakimab用于中重度特应性皮炎的常规治疗,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense pruritus and eczematous lesions. Tozorakimab is a high-affinity human monoclonal antibody that neutralizes interleukin-33, a broad-acting alarmin cytokine that is over-expressed in keratinocytes of patients with AD. OBJECTIVES: This Phase 2a study (FRONTIER-2; NCT04212169) evaluated the safety and efficacy of tozorakimab in adults with moderate-to-severe AD. METHODS: FRONTIER-2 was a randomized, placebo-controlled, parallel-group, double-blind study conducted from 9 December 2019 to 20 September 2022 at 32 centres across six countries. Patients were randomized 3:1:1:3 to receive placebo, tozorakimab 60 mg, tozorakimab 300 mg or tozorakimab 600 mg by subcutaneous injection once every 4 weeks for four doses. The primary endpoint was percentage change from baseline to Week 16 in the Eczema Area and Severity Index (EASI) score in patients treated with tozorakimab versus placebo. Secondary outcomes included EASI-75 responders (patients achieving ≥75% reduction from baseline in EASI score), Investigator's Global Assessment (IGA) responders (patients achieving an IGA score of 0 or 1), pharmacokinetics, immunogenicity and safety. RESULTS: Overall, 148 patients were randomized. There was no statistically significant difference in the primary endpoint (60 mg difference of 1.3 [90% confidence interval (CI): -13.7, 16.2], p = 0.888; 300 mg: difference of 5.9 [90% CI: -10.4, 22.1], p = 0.549; 600 mg: difference of - 1.7 [90% CI: -13.4, 10.0], p = 0.807). The proportion of EASI-75 and IGA 0/1 responders at Week 16 was numerically higher in the tozorakimab 600 mg group than in the placebo group (EASI-75: 18.2% vs. 7.1%, p = 0.094; IGA 0/1: 9.1% vs. 1.8%, p = 0.113). Serum pharmacokinetics were dose-dependent, immunogenicity incidence was low and tozorakimab was well tolerated. CONCLUSIONS: FRONTIER-2 did not show a statistically significant difference in the primary endpoint for tozorakimab compared with placebo. However, numerical increases in responder rates were observed.
引用
- Silverberg JI, Mustapa MN, Reid F, et al. Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2). J Eur Acad Dermatol Venereol. 2024. PMID: 39535462. doi:10.1111/jdv.20388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。